December 1, 2016 - By Pete Kolinski · 0 Comments
The stock of Dbv Tech SA Ads (NASDAQ:DBVT) registered an increase of 0.99% in short interest. DBVT’s total short interest was 396,800 shares in December as published by FINRA. Its up 0.99% from 392,900 shares, reported previously. With 71,500 shares average volume, it will take short sellers 6 days to cover their DBVT’s short positions. The short interest to Dbv Tech SA Ads’s float is 1.11%. The stock decreased 0.25% or $0.09 during the last trading session, hitting $36.52. DBV Technologies SA – ADR (NASDAQ:DBVT) has risen 6.53% since April 28, 2016 and is uptrending. It has outperformed by 0.61% the S&P500.
DBV Technologies SA is a France-based clinical-stage biopharmaceutical firm focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The company has a market cap of $1.80 billion. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It currently has negative earnings. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock.
Out of 8 analysts covering DBV Technologies (NASDAQ:DBVT), 8 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. DBV Technologies has been the topic of 8 analyst reports since August 11, 2015 according to StockzIntelligence Inc. Barclays Capital initiated DBV Technologies SA – ADR (NASDAQ:DBVT) on Thursday, December 3 with “Overweight” rating. JMP Securities initiated DBV Technologies SA – ADR (NASDAQ:DBVT) on Monday, September 26 with “Mkt Outperform” rating. The rating was maintained by Leerink Swann on Tuesday, August 11 with “Outperform”. The rating was upgraded by Vetr on Wednesday, September 2 to “Strong-Buy”. The company was initiated on Tuesday, September 15 by Morgan Stanley. The rating was initiated by Jefferies on Tuesday, October 13 with “Buy”. The rating was initiated by Bank of America on Friday, October 23 with “Buy”. Citigroup maintained DBV Technologies SA – ADR (NASDAQ:DBVT) rating on Wednesday, March 16. Citigroup has “Buy” rating and $43 price target.
More important recent DBV Technologies SA – ADR (NASDAQ:DBVT) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on October 22, 2014, also Fool.com published article titled: “Why Shares in DBV Technologies SA Are Soaring 10% Today”, Businesswire.com published: “Citi Appointed Depositary Bank for DBV Technologies’ ADR Programme” on October 28, 2014. More interesting news about DBV Technologies SA – ADR (NASDAQ:DBVT) was released by: Benzinga.com and their article: “The Baker Brothers Are Bullish On Seattle Genetics And DBV Technologies” with publication date: September 16, 2015.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Pete Kolinski